# BPC-157 Research Literature — Mechanism and Preclinical Findings by Pathway > Pathway-organized summary of BPC-157 preclinical and pilot human research: VEGFR2-Akt-eNOS angiogenesis, tissue repair, GI cytoprotection, cardiovascular protection, and the nitric oxide system. The BPC-157 research record is organized below by mechanistic pathway. Each pathway cluster identifies the primary signaling targets, key findings, dose and species context, and evidence tier. ## What the studies actually show The BPC-157 literature is organized around five mechanistic pathways — not a single target but a cluster of interacting signaling systems. The best-characterized is the VEGFR2-Akt-eNOS axis, which drives new blood vessel formation in injured tissue. A second pathway (Src-Caveolin-1-eNOS) governs vasomotor tone. Others involve tendon fibroblast growth-hormone-receptor signaling, FAK-paxillin cell-migration, and nitric-oxide-system modulation across multiple organs. Almost all published findings come from rats, mice, and in-vitro cell cultures. The compound has been studied across more than seven organ systems and the dose range in preclinical work spans roughly six orders of magnitude — an unusual feature that reviewers have noted without fully explaining. Three published human pilots exist (combined n=30), none of which were randomized. The 2025 University of Utah review concluded the preclinical musculoskeletal evidence is strong but that clinical use is not supported until controlled human trials are done. ## PATHWAY.01 / Angiogenesis — VEGFR2-Akt-eNOS and Src-Caveolin-1-eNOS The most studied signaling mechanism associated with BPC-157 is its activation of the vascular endothelial growth factor receptor 2 (VEGFR2) pathway. Angiogenesis — the formation of new blood vessels from existing vasculature — is the downstream output, and the mechanistic chain runs: BPC-157 promotes VEGFR2 internalization → Akt phosphorylation → eNOS activation → nitric oxide production → endothelial cell proliferation and migration. A 2017 study by Hsieh et al. demonstrated this pathway in both human umbilical vein endothelial cells (HUVECs) in vitro and rat hind-limb ischemia in vivo. At doses of 0.1–100 μg/mL in cell culture and 10 μg/kg intraperitoneal in rats, BPC-157 increased VEGFR2 mRNA and protein expression, accelerated blood-flow recovery in ischemic hind limbs, and increased vessel density — without altering VEGF-A levels directly [1]. The effect was VEGFR2-dependent: the compound acted on the receptor rather than on the ligand. The same research group examined BPC-157's vasomotor properties in a 2020 study using isolated rat aortic rings. At 0.1–100 μg/mL in ex-vivo organ bath preparations, BPC-157 produced 37.6% endothelium-dependent vasorelaxation at the maximal dose, mediated by phosphorylation of the Src-Caveolin-1-eNOS pathway. When the eNOS inhibitor L-NAME was applied, the vasorelaxant effect was abolished, confirming eNOS dependence. eNOS/Cav-1 binding was reduced by 50% in treated endothelial cells [2]. A notable nuance in the 2025 comprehensive review by Sikiric et al. is BPC-157's context-dependent dual angiogenesis behavior. In injured musculoskeletal tissue, BPC-157 promotes healing angiogenesis. In the cornea, it inhibits pathological neovascularization. The same nitric oxide system produces opposite effects depending on the pre-existing tissue state — a property the authors characterize as 'pleiotropic control of the NO system' [14]. This context-specificity has been noted as both a potential therapeutic advantage and a complication for modeling dose-effect relationships. The 2025 ocular study by Sikiric et al. extended the angiogenesis-inhibition observation into an IOP normalization context: topical BPC-157 eye drops at 0.4 μg to 0.4 ng per eye in rat glaucoma models rapidly and sustainably reduced intraocular pressure (≥24 hours per dose), preserved retinal ganglion cells, restored corneal transparency, and prevented new corneal vessel formation [13]. The same animals receiving per-oral dosing at 0.16 μg/mL showed comparable results. ## PATHWAY.02 / Tissue Repair — Tendon, Muscle, and Wound Tendon and musculoskeletal healing research constitutes the largest volume of published BPC-157 studies, spanning Achilles tendon transection, quadriceps detachment, muscle crush injury, myotendinous junction disruption, and six wound-healing model types. **Achilles tendon.** Staresinic et al. (2003) transected the Achilles tendon in rats and administered BPC-157 at 10 μg/kg IP for 14 days. Treated animals showed superior load-to-failure and Young's modulus of elasticity values at all measured time points, improved Achilles Functional Index scores, and histological evidence of dense mature collagen with organized vascular formation by post-operative day 4 [3]. In vitro, Chang et al. (2011) demonstrated that BPC-157 accelerated tendon explant outgrowth, protected tendon fibroblasts from H2O2-induced oxidative stress, and dose-dependently enhanced fibroblast migration in transwell assays [4]. **Growth hormone receptor upregulation.** Chang et al. (2014) reported up to sevenfold GHR mRNA and protein upregulation in rat tendon fibroblasts at 0.1–0.5 μg/mL by day 3. JAK2 phosphorylation was confirmed, and cell proliferation increased dose-dependently on both MTT and PCNA assays [5]. This finding raised research interest in the possible interaction between BPC-157 and exogenous GH secretagogues in connective tissue contexts; no co-administration studies have been published. **Muscle-to-bone reattachment.** Japjec et al. (2021) used a surgical quadriceps detachment model in rats and treated animals with BPC-157 at 10 μg/kg and 10 ng/kg via IP and per-oral routes. Full functional recovery (knee extension restored) was observed; defects disappeared in treated animals while controls showed progressive atrophy over 42 days. COX-2 mRNA decreased, eNOS mRNA increased, and the oxidative stress marker MDA was reduced [6]. A 2025 study by Matek et al. extended this model, confirming full walking-pattern recovery with Motor Function Index and Walking Recovery Index normalization; ultrasound showed gap closure at 21–28 days and MRI confirmed junction restoration at 90 days. Controls showed permanent healing failure throughout [17]. **Muscle crush injury.** Novinscak et al. (2008) administered BPC-157 daily for 14 days via both IP and topical cream routes following experimental muscle crush in rats, observing improved macroscopic, microscopic, and functional healing at all intervals; creatine kinase, LDH, and transaminase levels normalized [7]. **Wound healing.** Seiwerth et al. (2021) published a comprehensive review of BPC-157 wound-healing studies across six rodent model types: skin excision, incision, burn, alkali burn, diabetic ulcers, and fistulas. BPC-157 consistently accelerated collagen organization, re-epithelialization, and angiogenesis. In diabetic wound models it outperformed PDGF-BB. Fistula closure (colocutaneous, gastrocutaneous) was documented at doses ranging from 10 pg/kg to 10 μg/kg across IP, per-oral, and topical cream routes [8]. **2025 systematic narrative review.** McGuire et al. (2025) at the University of Utah synthesized all published human BPC-157 studies and the full preclinical musculoskeletal literature. Their review confirmed strong preclinical evidence for tendon and muscle repair, documented BPC-157's anti-inflammatory mechanisms (TNF-α, IL-6, and IFN-γ reduction; macrophage M1-to-M2 shift; HO-1 and heat shock protein upregulation; acetylcholine receptor stabilization), and estimated the plasma half-life at <30 minutes. The authors concluded that the compound 'should not be recommended for clinical use in musculoskeletal medicine' until well-designed human RCTs are conducted [16]. ## PATHWAY.03 / GI Cytoprotection and Hepatic Protection BPC-157's designation as a 'gastric pentadecapeptide' reflects its origin, and its most extensively published initial research context was cytoprotection of the gastrointestinal mucosa and liver. This pathway cluster includes NSAID-toxicity antagonism, fistula healing, and broader hepatic and multi-organ cytoprotection. **NSAID toxicity model.** Ilic et al. (2011) administered diclofenac at 12.5 mg/kg × 3 days in rats, producing severe combined GI, liver, and neurological toxicity. BPC-157 at 10 μg/kg and 10 ng/kg — both IP and per-oral in drinking water at 0.16 μg/mL and 0.16 ng/mL — antagonized these effects across all three organ systems. Severe gastric and intestinal lesions were prevented; elevated liver enzymes were normalized; hepatic encephalopathy (including brain edema and neuronal damage) was reversed; and sedation duration was normalized. The authors described treatment as 'strongly effective throughout the entire experiment' [9]. **Fistula healing.** Klicek et al. (2008) studied BPC-157 treatment of surgically created colocutaneous fistulas in rats, observing accelerated healing of both the colonic and skin defects and fistula closure via the nitric oxide system at 10 μg/kg and 10 ng/kg. This study also noted that BPC-157 — tested under the designation PL14736 in a Phase 2 IBD trial — was described as 'safe in clinical trials' based on that unpublished trial [20]. **Remote organ protection.** In the 2025 ischemia-reperfusion study by Demirtas et al., BPC-157 at 20 μg/kg IP prior to 45-minute lower-extremity ischemia in rats reduced remote organ injury across the kidney (reduced glomerular vacuolization and tubular dilation), lung (reduced alveolar congestion, edema, and leukocyte infiltration), and liver (reduced sinusoidal dilation and necrosis). Total antioxidant status (TAS) and paraoxonase-1 (PON-1) increased; total oxidative stress (TOS) and oxidative stress index (OSI) decreased across all three organs. The lung total damage score dropped from 6.00±0.52 to 3.33±0.92 (p=0.004) [11]. ## PATHWAY.04 / Cardiovascular and Neurological Cytoprotection **Cardiac.** Sikiric et al. (2022) summarized BPC-157 cardiac research across multiple rat models. In isoprenaline-induced myocardial infarction, BPC-157 at 10 μg/kg and 10 ng/kg normalized ECG findings (eliminating ST-T changes), preserved systolic left-ventricular function, reduced necrosis biomarkers (CK-MB, LDH, cTnT), and eliminated visible infarct on histology. Monocrotaline-induced pulmonary hypertension and right-heart failure were prevented. No proarrhythmic signal was observed across any tested arrhythmia model [10]. **Spinal cord.** Perovic et al. (2022) studied BPC-157 in rat sacrocaudal compression injury. At 2 μg/kg IP in early treatment and 10 ng/kg intragastric in delayed treatment, BPC-157 reduced spinal cord hematoma and swelling within 20 minutes of application, prevented demyelination, preserved myelin in white matter tracts on Luxol fast blue staining, and produced rapid sustained tail-function recovery. Spasticity resolved by day 15. Nos1, Nos2, and Nos3 mRNA was upregulated at the injury site [12]. **Safety margin.** The 2025 review by Sikiric et al. documented that LD1 was not achieved at 2 g/kg in mice via both intravenous and intragastric routes — the highest tested dose without a lethal outcome. The therapeutic dose range studied across preclinical models spans 10 pg/kg to 10 μg/kg, a six-log range across routes and species [14]. The McGuire et al. review placed this in regulatory context: the absence of a lethal dose in rodent safety testing, while notable, does not constitute human safety data, and the extremely limited human exposure makes extrapolation unreliable [16]. ## Human pilot data — the three published studies The published human data for BPC-157 consists of exactly three small studies. They are not randomized controlled trials. They are reported here as the complete scope of currently available human evidence — not as confirmation of safety or efficacy. **Knee pain retrospective series (Lee & Padgett, 2021).** Sixteen subjects with various musculoskeletal knee diagnoses received intra-articular BPC-157 injection. 87.5% reported significant pain relief. The study was retrospective, uncontrolled, and published in a peer-reviewed journal; no dose details are preserved in our research corpus for this study, so no specific dose is cited here. **Interstitial cystitis pilot (Lee, Walker & Ayadi, 2024).** Twelve women (mean age 58.3 years) with treatment-refractory interstitial cystitis received intravesicular BPC-157 injection at 10 mg total. All had previously failed pentosan polysulfate. At 6 weeks, 10 of 12 participants rated success at 100% resolution of moderate-to-severe symptoms; 2 of 12 rated success at 80%. Global Response Assessment showed significant improvement. No hematuria, acute cystitis, or other adverse events were reported [18]. **IV pharmacokinetic safety pilot (Lee & Burgess, 2025).** Two healthy adults (one 58-year-old male, one 68-year-old female) received BPC-157 by intravenous infusion — 10 mg on day 1 and 20 mg on day 2. No adverse events were reported. Vital signs, ECG, and all laboratory panels (cardiac, hepatic, renal, thyroid, metabolic) showed no clinically meaningful changes. Plasma BPC-157 levels returned to baseline within 24 hours, consistent with the estimated <30-minute plasma half-life [19]. The combined human evidence base has n=30 with heterogeneous routes, indications, and dosing protocols across three studies at a single research group. No randomized controlled trial of BPC-157 exists in the published literature. The McGuire et al. 2025 review identifies this absence as the primary gap before any clinical use could be considered [16]. --- An independent editorial record of the peer-reviewed literature — not a clinic, not a prescribing service.